<DOC>
	<DOCNO>NCT02129920</DOCNO>
	<brief_summary>Early recurrence cardioembolic stroke patient atrial fibrillation common , reach approximately 6 % within 30 day initial stroke . Therefore , preferable provide early anticoagulation cardioembolic stroke . However , early anticoagulation may increase risk hemorrhagic transformation cerebral infarct . It difficult decide time initiation anticoagulant therapy stroke patient non-valvular atrial fibrillation ( NVAF ) . In 2013 European Heart Rhythm Association present practical guide oral anticoagulant NVAF patient , recommend optimal time start anticoagulant therapy determine accord stroke severity . However , recommendation principally expert ' opinion suitable clinical practice Japan . RELAXED , multicenter observational study plan evaluate efficacy safety oral direct activate coagulation factor Xa inhibitor , rivaroxaban , acute ischemic stroke patient NVAF consideration infarct size , time initiation rivaroxaban medication , patient characteristic , thereby determine optimal time initiation acute ischemic stroke . The consecutive acute ischemic stroke / transient ischemic attack ( TIA ) patient NVAF treat rivaroxaban enrol . The infarction size 0-48 hour stroke onset measure diffusion weight image ( DWI ) MRI . The primary efficacy endpoint recurrent ischemic stroke within 3 month . The primary safety endpoint major bleeding within 3 month . The optimal timing initiate rivaroxaban acute ischemic stroke determine analysis co-relation primary endpoint infarct size / time initiate rivaroxaban .</brief_summary>
	<brief_title>RELAXED : Recurrent Embolism Lessened Rivaroxaban Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Clinical diagnosis acute ischemic stroke transient ischemic attack ( TIA ) Having nonvalvular atrial fibrillation Visiting clinic/hospital within 48 hour onset acute ischemic stroke TIA Identification infarct middle cerebral artery ( MCA ) territory ( symptom ascribable ischemia MCA territory TIA patient ) Initiation treatment rivaroxaban within 30 day onset acute ischemic stroke TIA Written inform consent patient hypersensitivity rivaroxaban 2 ) Active bleeding ( clinically significant hemorrhage ) include gastrointestinal hemorrhage liver disease complicate coagulation disorder liver disorder correspond ChildPugh Class B C renal failure ( creatinine clearance : &lt; 15 mL/minute ) poorly control hypertension ( high 180/100 ) Woman likely pregnant Ongoing treatment HIV protease inhibitor include ritonavir , atazanavir indinavir Ongoing treatment itraconazole , voriconazole ketoconazole Active bacterial endocarditis Patients consider investigator unsuitable participating study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Cerebral Infarction</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Arrhythmias , Cardiac</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Cerebrovascular Disorders</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Brain Infarction</keyword>
	<keyword>Brain Ischemia</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>